Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues.

× No keyword cloud information.

12 in total

1. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriales infection: are they the same in neutropenic and non-neutropenic patients?

Authors: Filippo Lagi; Giampaolo Corti
Journal: Intern Emerg Med Date: 2019-02-08 Impact factor: 3.397

2. Evaluation of Empiric β-Lactam Susceptibility Prediction among Enterobacteriaceae by Molecular β-Lactamase Gene Testing.

Authors: Kyle Spafford; Shawn MacVane; Romney Humphries
Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948

3. Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.

Authors: Fabian Bernhard; Rajesh Odedra; Sylvie Sordello; Rossella Cardin; Samantha Franzoni; Cédric Charrier; Adam Belley; Peter Warn; Matthias Machacek; Philipp Knechtle
Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191

Review 4. Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.

Authors: Gisele Peirano; Johann D D Pitout
Journal: Drugs Date: 2019-09 Impact factor: 9.546

5. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.

Authors: Adam Belley; Michael D Huband; Kelley A Fedler; Amy A Watters; Robert K Flamm; Stuart Shapiro; Philipp Knechtle
Journal: J Clin Microbiol Date: 2019-07-26 Impact factor: 5.948

6. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.

Authors: Keith S Kaye; Adam Belley; Philip Barth; Omar Lahlou; Philipp Knechtle; Paola Motta; Patrick Velicitat
Journal: JAMA Date: 2022-10-04 Impact factor: 157.335

7. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis.

Authors: Burcu Isler; Yukiko Ezure; Jose Luis García-Fogeda Romero; Patrick Harris; Adam G Stewart; David L Paterson
Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191

Review 8. Carbapenem-Sparing Strategies for ESBL Producers: When and How.

Authors: Ilias Karaiskos; Helen Giamarellou
Journal: Antibiotics (Basel) Date: 2020-02-05

9. Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection.

Authors: Yuzhu Dong; Ying Li; Ying Zhang; Dan Sun; Qian Du; Tao Zhang; Mengmeng Teng; Ruiying Han; Yan Wang; Li Zhu; Jin'e Lei; Yalin Dong; Taotao Wang
Journal: Infect Drug Resist Date: 2020-05-07 Impact factor: 4.003

10. PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales.

Authors: David L Paterson; Burcu Isler; Patrick N A Harris
Journal: JAC Antimicrob Resist Date: 2021-02-24